18-21 July 2018 Dublin
![]() |
![]() |
![]() |
![]() |
PB-001 | Platelet Chemokine Receptor CXCR7 Mediates an Anti-thrombotic and Anti-thromboinflammatory Effect | Madhumita Chatterjee | ![]() |
![]() |
|||
PB-002 | Ticagrelor Inhibits Platelet-induced Formation of Neutrophil Extracellular Traps | Iraklis C. Moschonas | ![]() |
![]() |
|||
PB-007 | Beta-1,4-galactosyltransferase 2 c.909C>T Gene Variant Is Predictive of On-clopidogrel Platelet Reactivity | Tiphaine Belleville-Rolland | ![]() |
![]() |
|||
PB-008 | High On-treatment Platelet Reactivity (HTPR) on Clopidogrel but Not on Novel P2Y12 Antagonists in Patients with ACS Undergoing PCI - Single Centre Study | Ján Staško | ![]() |
![]() |
|||
PB-009 | Detection of Anthocyanins Effects to Alleviating Thrombotic Risks in Comparison to Aspirin | Almottesembellah Gaiz | ![]() |
![]() |
|||
PB-011 | Assessment of Clopidogrel Response in Patients with Prior Atherothrombotic Events | Zühre Kaya | ![]() |
![]() |
|||
PB-014 | Results of Platelet Aggregation Testing by Light Transmission Aggregometry using Drug Specific Agonists in Patients Taking Antiplatelet Therapy | Sandra Margetic | ![]() |
![]() |
|||
PB-017 | Impact of Time-to-treatment on Freedom-from-relapse for Steroid-Refractory Immune Thrombocytopenia | Prakash Vishnu | ![]() |
![]() |
|||
PB-018 | Guidance on the Diagnosis and Management of PT-VWD: A Project from the Platelet Physiology Subcommittee of the ISTH | Maha Othman | ![]() |
![]() |
|||
PB-019 | PK Simulation of Avatrombopag-induced Increases in Platelet Counts with Redosing in Patients with Thrombocytopenia and Chronic Liver Disease | Kavita Aggarwal | ![]() |
![]() |
|||
PB-020 | Exploratory Analyses of the Efficacy of Avatrombopag versus Placebo from 2 Phase 3 Studies Using Alternate Baseline Platelet Count Cohorts and an Alternate Secondary Efficacy Endpoint | Kavita Aggarwal | ![]() |
![]() |
|||
PB-021 | Influence of Preoperative Platelet Activity on Coagulation and Blood Loss in Large Orthopedic Surgery | Irina Antropova | ![]() |
![]() |
|||
PB-022 | Superiority of Avatrombopag to Placebo in Increasing Platelet Counts and Reducing Platelet Transfusions in Patients with Chronic Liver Disease-associated Thrombocytopenia Undergoing Scheduled Procedures - Pooled Analysis of 2 Randomized Phase 3 Studies | Kavita Aggarwal | ![]() |
![]() |
|||
PB-023 | Atypical Presentations of RUNX1 Associated Familial Platelet Disorder with Predisposition to Myeloid Malignancy (FPDMM) | Christopher Ward | ![]() |
![]() |
|||
PB-024 | Population PK/PD Modeling of Avatrombopag in Patients with Thrombocytopenia and Chronic Liver Disease - Guided Phase 3 Dose Selection | Kavita Aggarwal | ![]() |
![]() |
|||
PB-026 | Bloody Diarrhea with Thrombocytopenia in Male Children: Think of Wiskott Aldrich Syndrome | Deepti Suri | ![]() |
![]() |
|||
PB-027 | Pseudothrombocytopenia: Beyond Platelets Aggregates | Anália Carmo | ![]() |
![]() |
|||
PB-028 | Coagulation Abnormalities in Dengue and Dengue Hemorrhagic Fever Patients in Pakistan | Jawad Hassan | ![]() |
![]() |
|||
PB-030 | Acquired Platelet Function Defect and Moderate Cutaneous Bleeding in a Patient on Treatment with a Leukotriene Receptor Antagonist for Asthma | Marina Marchetti | ![]() |
![]() |
|||
PB-031 | Pelvic Hematoma Secondary to Glanzmann´s Thrombasthenia: A Case Report | Siong Leng Hon | ![]() |
![]() |
|||
PB-033 | Platelet´s Disorder in a Case of Chronic Lymphocytic Leukemia | Corrado Lodigiani | ![]() |
![]() |
|||
PB-035 | Dichotomous Cytosolic Mobilization of Calcium, Sodium and Potassium Ions during Procoagulant COAT Platelet Formation | Alessandro Aliotta | ![]() |
![]() |
|||
PB-036 | Emerging Value of Platelet Function Testing at Predicting the Risk of Recurrent Vascular Events and Outcomes after TIA/Ischemic Stroke: A Systematic Review of the Literature | Soon Tjin Lim | ![]() |
![]() |
|||
PB-037 | Lysis of Blood Cells by Arachidonic Acid Cause ADP-dependent Platelet Activation Responses in Platelet Function Tests using Whole Blood | Sofia Ramstrom | ![]() |
![]() |
|||
PB-038 | Assessment of Platelet Count Standardization in Platelet-rich Plasma for Platelet Function Testing by Light Transmission Aggregometry | Mason Dixon | ![]() |
![]() |
|||
PB-039 | Kinetic Application of Flow Cytometry for Patients with Unknown Bleeding Disorders: The Underestimated Value of Mepacrine | Georgi Manukjan | ![]() |
![]() |
|||
PB-040 | The Gp1ba-Cre Transgenic Mouse: A New Model to Delineate Platelet and Leukocyte Functions | Zoltan Nagy | ![]() |
![]() |
|||
PB-041 | The Fluidity of Platelet Membrane an Important Parameter for Platelet Function in Chronic Myeloproliferative Neoplasms Patients | Viola Maria Popov | ![]() |
![]() |
|||
PB-042 | The Effect of FXa on Platelet Activation, in vitro | Styliani Papadaki | ![]() |
![]() |
|||
PB-043 | Functional Validation of microRNA-126-3p as a Platelet Reactivity Regulator using Human Progenitor Cells | Alix Garcia | ![]() |
![]() |
|||
PB-044 | Assessment of Light Transmission Aggregometry on the Routine Coagulation Analyzer Siemens CS-2500 using CE-marked Agonists from Hyphen Biomed | Mathieu Fiore | ![]() |
![]() |
|||
PB-047 | Influence of Sample Platelet Count on Three Common Platelet Function Tests: A Comparative Study | Anna L. Södergren | ![]() |
![]() |
|||
PB-048 | Comparison of PAC-1 and a-fibrinogen Antibody Binding to Platelet Subpopulations | Anna L. Södergren | ![]() |
![]() |
|||
PB-049 | Assessment of Neonatal Platelet Granule Trafficking and Shear-induced Platelet Activation in Neonatal Peripheral and Cord Blood | Anh Ngo | ![]() |
![]() |
|||
PB-053 | Platelets Role in the Plasma Clotting is Not Limited to Providing a Lipid Surface | Anna Balandina | ![]() |
![]() |
|||
PB-054 | Stability of Platelet Function in Healthy Individuals over a One-year Period | Mark Roest | ![]() |
![]() |
|||
PB-055 | The Canine Platelet Secretome (CAPS): Proteomic Analysis of Thrombin-stimulated Release | Signe Emilie Cremer | ![]() |
![]() |
|||
PB-057 | Mean Platelet Volume Positively Correlates with Uterine Volume after Menopause, Except Myomas Presence | Bibiána Bajteková | ![]() |
![]() |
|||
PB-061 | Flow Cytometric Analysis of Platelet Function in Patients on Antiplatelet Therapy and Suspected Thrombocytopathy | Dana Huskens | ![]() |
![]() |
|||
PB-062 | Characterization of Platelet Function with Flow Cytometry for Bleeding Risk Evaluation in Hematological Disorders | Anastasia Ignatova | ![]() |
![]() |
|||
PB-065 | Usefulness of Optical Aggregometry and Flow Cytometric Studies as a Complementary Tools in Patients with Acquired Platelet Defects (APD) | Analia Sanchez-Luceros | ![]() |
![]() |
|||
PB-066 | Platelet Function in Polycythemia Vera and Primary Myelofibrosis Using Multiple Electrode Aggregometry | Nikolaj Skrøder Nytofte | ![]() |
![]() |
|||
PB-067 | Platelet to Lymphocyte Ratio was Significantly Lower for Slovak Postmenopausal Women Born from November to April, Except those with Leiomyoma | Bibiána Bajteková | ![]() |
![]() |
|||
PB-069 | A Novel Role of LASSBio-788 in Inhibiting NF-?B Mediated Signaling in Platelet of Hypercholesterolemic Rats: Would Be New Antiplatelet Agent? | Nadia Alice Vieira Motta | ![]() |
![]() |
|||
PB-070 | New Clinicopathologic Finding in a Patient with Acquired Amegakaryocytic Thrombocytopenia Treated with Thrombopoietin Receptor Agonist Therapy | eva hortas | ![]() |
![]() |
|||
PB-075 | Evidence of a Dominant Negative Effect of Gain-of-Function ITGB3 Mutations over Loss-of Function Mutations in Variant Glanzmann Thrombasthenia | Loredana Bury | ![]() |
![]() |
|||
PB-076 | Bleeding Diathesis Associated with Severe Acquired Platelet Dysfunction and Overproduction of Cyclic AMP in Two Patients with Hematologic Malignancies | Andrea Artoni | ![]() |
![]() |
|||
PB-077 | In-silico Prediction of Molecular Mass Distance Dependent Changes in Binding Energies between von Willebrand Factor and Platelet Membrane Glycoprotein (GP) Iba in Wild Type and G233V Mutant | Shinichi Goto | ![]() |
![]() |
|||
PB-079 | Investigation of Polymorphic Variations in Glutathione S Transferase Genes among Immune Thrombocytopenia Patients in Pakistan | Samina Naz Mukry | ![]() |
![]() |
|||
PB-081 | CD8 T Cell-mediated Platelet Clearance Does Not Occur via Traditional Cytotoxic Protein Killing | Cheryl Maier | ![]() |
![]() |
|||
PB-082 | Human Platelets Labeled at Multiple Biotin Densities: A Promising Approach for Monitoring in vivo Platelet Survival in Clinical Trials | Catherine Ravanat | ![]() |
![]() |
|||
PB-083 | Quantitative Alteration of Vesicle Associated miRs and RISC Complex Reflect Platelet Concentrate Molecular Pattern during Storage as Platelets Activity Model | Vasilii Kishenko | ![]() |
![]() |
|||
PB-084 | Improving Transfusion Safety by Implementing Platelet Bacterial Screening in a Resource-limited Country | Farheen Karim | ![]() |
![]() |
|||
PB-089 | Compensatory Effect of Fibrinogen in Patient with Bone Marrow Aplasia, Septic Shock and Severe Thrombocytopenia Guided by Thromboelastometry: A Case Report | Tomaz Crochemore | ![]() |
![]() |
|||
PB-090 | A Novel Murine Model of Immune Thrombocytopenia Induced by Immunized CD41 Knockout Mice | Xin Li | ![]() |
![]() |
|||
PB-092 | Effects of Bothrops jararaca Venom on Platelet Aggregation, Secretion and Protein synthesis | Marcelo L. Santoro | ![]() |
![]() |
|||
PB-095 | Janus Kinase 3 (JAK3)-dependent Signaling Is Critical to Ca2+-dependent Platelet Activation and Thrombus Formation | Mailin Manke | ![]() |
![]() |
|||
PB-098 | Role of Protease-activated Receptor 4 in Regulating Platelet Dense Granule Release | Tiffany Chu | ![]() |
![]() |
|||
PB-103 | S100A9 Activates Platelets via RAGE | Saskia von Ungern-Sternberg | ![]() |
![]() |
|||
PB-105 | Induced Apoptosis-like Changes Caused by Sirtinol, a Pharmalogic Inhibitor of Sirt1/2, in Human Platelets | Ram L. Mallick | ![]() |
![]() |
|||
PB-106 | Tumor Necrosis Factor Receptor Associated Factor 6 (TRAF6) in the Pathogenesis of Immune Thrombocytopenia | Elif Umit | ![]() |
![]() |
|||
PB-107 | Patients with Aortic Stenosis Have von Willebrand Factor Abnormalities and Aberrant Angiogenesis in BOEC | Soundarya Nivedita Selvam | ![]() |
![]() |
|||
PB-108 | High-dose Dexamethasone Alters the Increase in IL-16 Level in Adult Immune Thrombocytopenia | Xinyi Zuo | ![]() |
![]() |
|||
PB-109 | Progranulin Facilitates the Increase of Platelet Count in Immune Thrombocytopenia | Xinyi Zuo | ![]() |
![]() |
|||
PB-110 | The Aberrant Expression of microRNAs in B Lymphocytes of Patients with Immune Thrombocytopenia | Xi Jia | ![]() |
![]() |
|||
PB-111 | A Novel Model using Protein C-to-INR Ratio to Predict Short-term Mortality in Cirrhosis | Anupama Patil | ![]() |
![]() |
|||
PB-112 | Increased Cytotoxic Potential of CD8 T Cells in Patients with Immune Thrombocytopenia | John R Vrbensky | ![]() |
![]() |
|||
PB-113 | Gene Expression of Vanin-1 (VNN-1) in Egyptian Adults with Immune Thrombocytopenia (ITP): A Single Center Experience | Doaa El Demerdash | ![]() |
![]() |
|||
PB-115 | Real-life Bleeding Risk of Anti-factor Xa Direct Oral Inhibitors; Does Prothrombin Complex Concentrate Work? | Buddhika Badugama | ![]() |
![]() |
|||
PB-117 | Is the Profile of Patients with Intracranial Hemorrhage Changing? | Sarah Reeves | ![]() |
![]() |
|||
PB-120 | Noonan Syndrome and Bleeding Disorders: An Overview of Current Diagnostic Management | C.H. van Ommen | ![]() |
![]() |
|||
PB-121 | Long-Term Follow-up of Children on Prophylaxis for Severe Factor VII Deficiency in Lebanon | Roula A. Farah | ![]() |
![]() |
|||
PB-122 | Clinical Presentations and Diagnostic Algorithm of Neonatal FXIII-deficiency | Mehran Karimi | ![]() |
![]() |
|||
PB-123 | Effectiveness of Pediatric Bleeding Questionnaire in Hemorrhagic Disorders | Laura Villarreal Martinez | ![]() |
![]() |
|||
PB-124 | Surgical Management of Rare Factor Deficiencies | Erol Erduran | ![]() |
![]() |
|||
PB-127 | Plasma Profile of Platelet Auto-antibodies in Patients with Thrombocytopenia in Pregnancy | Wenhong Shen | ![]() |
![]() |
|||
PB-131 | Translation and Validation of the Pictorial Blood Loss Assessment Chart (PBAC) in Arabic | Ons Kaabia | ![]() |
![]() |
|||
PB-132 | Diagnosis Value of Screening Tools for Hemostasis Disorders in Women Consulting for Prolonged Menstruation with Normal Pelvic Exam | Ons Kaabia | ![]() |
![]() |
|||
PB-133 | Clinical Screening for Underlying Bleeding Disorder in Nigerian Women | Theresa Nwagha | ![]() |
![]() |
|||
PB-134 | Hemostasis Disorders in Tunisian Women with Non Organic Menorrhagia: A Case Control Pilot Study | Ons Kaabia | ![]() |
![]() |
|||
PB-135 | Improving the Gynaecological Management of Women with Bleeding or Thrombotic Disorders by Multi-professional Out-patient Care | Kathryn Mary Musgrave | ![]() |
![]() |
|||
PB-136 | A Woman´s Life-long Bleeding Condition: Diagnostic Dilemma and Expert Opinion | Rochelle Winikoff | ![]() |
![]() |
|||
PB-137 | Thrombocytopenia in Pregnancy: The Role of Hemostasis Laboratory for Diagnosis and Management of Acute Fatty Liver of Pregnancy | Giuseppe Rescigno | ![]() |
![]() |
|||
PB-139 | Does Hemophilia Slow Down the Development of Liver Fibrosis? | Marie-Astrid van Dievoet | ![]() |
![]() |
|||
PB-140 | Geno- and Phenotype Correlate in Porcine Model of von Willebrand Disease Type 1 and Type 3 | Hanna Allerkamp | ![]() |
![]() |
|||
PB-142 | Recombinant Expression of F9 Nonsense Mutations and Fix Pharmacokinetics in Hemophilia B | Massimo Morfini | ![]() |
![]() |
|||
PB-148 | Circulating Biochemical Markers of Early Joint Bleeding: Validation Study in Humans | Narine Hakobyan | ![]() |
![]() |
|||
PB-152 | Whole F8 and VWF Gene Sequencing using Next-generation Sequencing for Mutation-negative French and Canadian Hemophilia A Patients | Fanny Lassalle | ![]() |
![]() |
|||
PB-153 | Within-patient Comparison of Treatment Patterns before and after Switching to rFIXFc: A Report from the UK National Haemophilia Database | Martin Scott | ![]() |
![]() |
|||
PB-154 | Arthropathy and Joint Replacement Surgery in Patients with Hemophilia A (PwHA) in the US | Anisha Patel | ![]() |
![]() |
|||
PB-155 | Extended Half-life Factor Concentrate Use for Patients with Moderate and Severe Hemophilia among ATHN-affiliated U.S. Hemophilia Treatment Centers | Stacy E. Croteau | ![]() |
![]() |
|||
PB-156 | Genetic Polymorphisms Contributing to the Pharmacokinetics of Factor VIII Concentrates | Massimo Morfini | ![]() |
![]() |
|||
PB-157 | Real World Data Analysis of US Claims Database on Coagulation Factor VIII Expenditures in Patients with Hemophilia A: Standard Half-life vs. Extended Half-life Products | Bartholomew Tortella | ![]() |
![]() |
|||
PB-158 | Measuring FIX-Activity of Nonacog Beta Pegol (N9-GP) in a One-stage Ellagic Acid Based Clot Assay on the ACL TOP 50 Series Instrument: A Two-site Study | Mary Doyle | ![]() |
![]() |
|||
PB-161 | Correlation of Factor Levels with Bleeding Phenotype in Non-severe Hemophilia | Ingrid Pabinger | ![]() |
![]() |
|||
PB-164 | Burden of Mild Hemophilia A: Systematic Literature Review | Eva Hortas | ![]() |
![]() |
|||
PB-165 | Realworld Health Care Expenditure and Dispensation of Extended and Standard Half-life Recombinant Factor IX Products in Hemophilia B Patients | Bartholomew Tortella | ![]() |
![]() |
|||
PB-168 | The Effect of Unmeasurable Endogenous Plasma Factor Activity Levels on Factor VIII Dosing in Patients with Severe Hemophilia A | Pierre Chelle | ![]() |
![]() |
|||
PB-171 | Are Current Therapeutic Strategies with Conventional Products Sufficient to Manage the Burden of Haemophilia in Italy? | eva hortas | ![]() |
![]() |
|||
PB-172 | Practical Considerations in Choosing a Cost-effective and-Efficient Solution for Prophylaxis in Haemophilia | Margit Serban | ![]() |
![]() |
|||
PB-179 | The Bone Disease in Haemophilia: The Role of von Willebrand Factor, Factor VIII and Thrombin | Stefano Lancellotti | ![]() |
![]() |
|||
PB-181 | Standardized Determination of FVIII Inhibitors with the Improved FVIII INH Kit | Lieselotte Wagner | ![]() |
![]() |
|||
PB-185 | Joint and Functional Assessment Following Secondary and Tertiary Prophylaxis in PWH who were Previously Receiving Episodic on Demand Factor Replacement Infrequently | Anupam Dutta | ![]() |
![]() |
|||
PB-187 | Epidemiological Survey and Audit of Socio-demographic Characteristics of Patients with Haemophilia and other Congenital Bleeding Disorders | Helen Okoye | ![]() |
![]() |
|||
PB-188 | Development of a FVIII Antigen Assay to Quantify B-domain Deleted FVIII Antigen in Human Plasma | eva hortas | ![]() |
![]() |
|||
PB-192 | Hemophilia A Subjects with an Intron-22 Inversion Mutation Show Robust T-cell Responses to Epitopes in Both the FVIII Heavy and Light Chain | Kathleen P. Pratt | ![]() |
![]() |
|||
PB-197 | Potential Clinical Trial Validation of Differential EPCR-dependent Activity by Eptacog Beta, a rhFVIIa Variant, in the Treatment of Bleeding in Hemophilia Patients with Inhibitors | Jonathan Ducore | ![]() |
![]() |
|||
PB-200 | Risk Modeling Inhibitor Development of Haemophilia A Patients in Australia | Sumit Parikh | ![]() |
![]() |
|||
PB-203 | Successful Eradication of Factor FVIII Inhibitor by Cyclophosphamide Treatment in a Patient with Acquired Haemophilia A - A Case Report | Sandra Margetic | ![]() |
![]() |
|||
PB-204 | Clinical Description and Laboratory Characterization of Heparin-like Substance Causing Bleeding | Jun Teruya | ![]() |
![]() |
|||
PB-206 | Skeletal and Cardiac Muscle Myosin Exert Procoagulant and Antifibrinolytic Effects | Julia Coleman | ![]() |
![]() |
|||
PB-210 | Platelet-nanocapsule Hybrids for On-demand, Targeted Delivery of Factor VIII in Hemophilia A Mice | Caroline E. Hansen | ![]() |
![]() |
|||
PB-211 | Annualized Bleeding Rates, the Current Favorite Clinical Endpoint in Hemophilia Trials: Pitfalls and Caveats | Christine Keipert | ![]() |
![]() |
|||
PB-214 | Tranexamic Acid Reduces Post-surgical Infection Rates via Direct Immune Cell Modulation | Dominik F. Draxler | ![]() |
![]() |
|||
PB-215 | ROTEM® or Conventional Hemostasis Test: Experience in Cardiac Surgery Setting | Isabelle Gouin-Thibault | ![]() |
![]() |
|||
PB-216 | A New, Hand-held, Multifunctional Coagulation Laboratory for Perioperative Monitoring | Seemantini Nadkarni | ![]() |
![]() |
|||
PB-218 | Monitoring Anticoagulation and Hemostasis in Cardiac Surgical Patients with a Drop of Whole Blood | Diane Malu Tshikudi | ![]() |
![]() |
|||
PB-219 | Short-term Recovery Pattern of Plasma Fibrinogen after Cardiac Surgery: A Prospective Observational Study | Gabor Erdoes | ![]() |
![]() |
|||
PB-221 | Classification of Surgical Bleeding Situations | Richard Kocharian | ![]() |
![]() |
|||
PB-222 | Recombinant Factor VIIa (Novoseven®) Utilization and Safety for Refractory Bleeding After Cardiac Surgery at a Large Academic Medical Center | Tania Ahuja | ![]() |
![]() |
|||
PB-224 | Thromboelastometry-guided Therapy for the Treatment of Hemorrhagic Shock in Postoperative of Vascular Surgery: A Case Report | Tomaz Crochemore | ![]() |
![]() |
|||
PB-225 | Analysis of Fresh Frozen Plasma Requirement in Post Cardiopulmonary Bypass Cardiac Surgery Patient Based on Standard Coagulation and Thrombelastography Tests in Hasan Sadikin Hospital, Bandung | Leni Lismayanti | ![]() |
![]() |
|||
PB-226 | Quality and Accuracy of Testing for von Willebrand Disease by North American Special Coagulation Laboratories from 2010 to 2017 | Jameel Abdulrehman | ![]() |
![]() |
|||
PB-227 | FXI-deficient Patients with Bleeding Phenotype Show a Spatio-temporal Propagation of Blood Coagulation Shorter and Slower than Normal | Debora Bertaggia Calderara | ![]() |
![]() |
|||
PB-228 | The FVIII: C Measurement of Extended Half-life Recombinant Factor VIII FC Fusion in Haemophilia A Patients | Annette Bowyer | ![]() |
![]() |
|||
PB-229 | Overassignment of Recombinant Wild Type (rwt) FIX Potency by a One-stage Method Indicated from Comparison with Chromogenic FXIa and TF/FVIIa Based Methods and through Discrepant Activation of rwt FIX and Plasma Derived (pd) FIX by Plasma Kallikrein (PK) | Steffen Rosén | ![]() |
![]() |
|||
PB-230 | Sensitive and Standardized TGA Measurement in Haemophilia Patients Using Ceveron® Alpha TGA | Nikolaus B. Binder | ![]() |
![]() |
|||
PB-231 | Differences in FVIII Measurements of Plasma Spiked with AFSTYLA® Generated with One-stage Clotting Assay using Different Commercial APTT Reagents Compared with Chromogenic Method | Inge Vangenechten | ![]() |
![]() |
|||
PB-233 | Pre - analytical Variables - Sample Rejection in Hemostasis Laboratories | Lilia Brown | ![]() |
![]() |
|||
PB-234 | Thromboelastometry Profile in Critically Ill Patients: A Single-center, Retrospective, Observational Study | Tomaz Crochemore | ![]() |
![]() |
|||
PB-235 | Differences in Activity of Plasma Spiked with IDELVION® Generated with One-stage Clotting Assay using Different Commercial APTT Reagents Compared with Chromogenic Method | Inge Vangenechten | ![]() |
![]() |
|||
PB-236 | Extended Half-life Factor VIII: From Biology to Patients´ Management Optimization | Andreas Perrier-Cornet | ![]() |
![]() |
|||
PB-237 | Evaluation of an Automated Chromogenic Assay for Measuring FVIII:C Levels in the Patients Affected by Hemophilia A | Cristina Novembrino | ![]() |
![]() |
|||
PB-238 | Underassignment of FIX Potency of rFIX-Albumin Fusion Protein (rFIX-HSA) by One Stage Methods Demonstrated in Studies on FXIa and FIXa Generation | Steffen Rosén | ![]() |
![]() |
|||
PB-239 | Correlation of FIX Activity Assays with Thrombin Generation | Lisa Florin | ![]() |
![]() |
|||
PB-243 | One Stage and Chromogenic Assays Discrepancy in the Estimation of Factor IX (FIX) Recovery. What is it that a Single Hemophilia Center Can and Cannot Do? | Jovan P Antovic | ![]() |
![]() |
|||
PB-244 | Comparison of Two One-stage Clotting Assays and One Chromogenic FIX Assay for Monitoring of Idelvion® Replacement Therapy | Lisa Florin | ![]() |
![]() |
|||
PB-245 | Levels of Coagulation Factors, Coagulation Inhibitors and TAFI Do Not Affect Global Hemostasis and Bleeding Phenotype in Patients with Hemophilia A | Jovan Antovic | ![]() |
![]() |
|||
PB-247 | The Effect of DDAVP on Thrombin Generation in Patients with Bleeding Disorders | Alexandra Agapidou | ![]() |
![]() |
|||
PB-249 | Comparison of Three Thromboplastin Reagents for International Normalized Ratio (INR) Measurement in Patients on Vitamin K Antagonist Therapy | Francois Depasse | ![]() |
![]() |
|||
PB-251 | External Quality Assurance (EQA) for the Rotem Sigma Thromboelastometry Device | Dianne Kitchen | ![]() |
![]() |
|||
PB-252 | Stored Calibration Curves Can Deliver Acceptable Accuracy and Precison on CS5100 Analysers | Anne Sermon-Cadd | ![]() |
![]() |
|||
PB-253 | Measurement of Immunoglobulins Anti VWF in Patients with Probable AVWS with an Enzyme-linked Immunosorbent Assay (ELISA) Using Platelet VWF as an Antigen | Analia Sanchez-Luceros | ![]() |
![]() |
|||
PB-254 | Performance Evaluation of Automated Thrombin Generation Measurement on Ceveron®alpha TGA | Lieselotte Wagner | ![]() |
![]() |
|||
PB-255 | Calibrations Performed in the Lab Fail to Correct Fibrinogen Quality Control Variability Generated by Different Reactant Batches | Felipe Guerrero | ![]() |
![]() |
|||
PB-257 | Variations in Automated Platelet Counts Occur Depending on the Principle Used for Cell Counting and on the Non-platelet Blood Cell Parameters | Ganesh Kumar Viswanathan | ![]() |
![]() |
|||
PB-258 | Accuracy and Precision of Point-of-Care International Normalized Ratio (INR) in Pediatric and Adult Patients with Liver Disease Pilot Study | Patricia Sachi Kawada | ![]() |
![]() |
|||
PB-259 | Clearance of Mouse VWF Propeptide Is Mediated by Stabilin-2 and Is Regulated by N-linked Glycan Expression | Orla Rawley | ![]() |
![]() |
|||
PB-261 | Expression of the SCARA5 Scavenger Receptor in the Human Kidney and Spleen May Regulate Clearance of VWF | Laura L Swystun | ![]() |
![]() |
|||
PB-262 | Diverse Inheritance of VWD Found in Type 3 U.S. Families in the Zimmerman Program | Pamela Christopherson | ![]() |
![]() |
|||
PB-264 | High Molecular Weight von Willebrand Factor Multimers in Cryoprecipitate Exceed that Found in a Commercial Concentrate | Meaghan Elizabeth Colling | ![]() |
![]() |
|||
PB-270 | Molecular Analysis and Bleeding Phenotype of Seven Severe FV-deficient Patients from Pakistan | Munira Borhany | ![]() |
![]() |
|||
PB-271 | Rare Bleeding Disorders in Pakistan: An Update | Munira Borhany | ![]() |
![]() |
|||
PB-272 | Functional Polymorphisms of the von Willebrand Factor Gene in Patients with Mild to Moderate Bleeding Tendency and Low or Normal von Willebrand Factor Antigen or von Willebrand Factor Ristocetin Cofactor | Stefanie Hofer | ![]() |
![]() |
|||
PB-273 | Comparison of a von Willebrand Factor Fully-automated Chemiluminescent Assay Panel for von Willebrand Disease Diagnosis to and Historical Classification | Luciano Baronciani | ![]() |
![]() |
|||
PB-275 | Correction of Factor XI Deficiency by Liver Transplantation for Secondary Sclerosing Cholangitis | Corinne Frere | ![]() |
![]() |
|||
PB-276 | Intense Exercise Increases von Willebrand Factor and Factor VIII Levels in Well-trained Athletes | Paraskevi Spatharaki | ![]() |
![]() |
|||
PB-277 | Prevalence of von Willebrand Disease among Nigerian Youths in Ibadan South-Western Nigeria | Wuraola Shokunbi | ![]() |
![]() |
|||
PB-278 | Impact of Mitral Valve Clip Procedure on Indices of Acquired von Willebrand Syndrome | Joseph Blackshear | ![]() |
![]() |
|||
PB-279 | Comparative Study of Single Nucleotide Polymorphisms (SNPs) in the Exon 28 of the VWF between Healthy Donors, VWD2M (with p.E1549K and p.R1374C) and VWD2B Patients (with p.R1308C and p.V1316M) in a Single Center in Argentina. Preliminary Report | Analia Sanchez-Luceros | ![]() |
![]() |
|||
PB-280 | Genotyping of Five Patients with Severe Inherited Factor X (FX) Deficiency from Pakistan: Identification of Two Novel Mutations | Munira Borhany | ![]() |
![]() |
|||
PB-282 | Discrepant von Willebrand Factor (VWF) Activity Levels in Two Unrelated von Willebrand Disease (VWD) Patients | Mackenzie Bowman | ![]() |
![]() |
|||
PB-284 | Are Iranian Patients with von Willebrand Disease Type 2N Properly Differentiated from the Ones with Mild/Moderate Hemophilia A and Do They Receive Appropriate Treatment? | Asghar Seidi Zadeh | ![]() |
![]() |
|||
PB-285 | Polyphoshate Nanoparticles Slow Down the Clotting of Fibrinogen and Increase the Lytic Stability of Fibrin | Miklós Lovas | ![]() |
![]() |
|||
PB-286 | Alternative Complement Pathway Inhibits Fibrinolysis in an in-vitro Whole Blood Model | Jason Samuels | ![]() |
![]() |
|||
PB-290 | Novel Fibrinogen Missense Mutations in Patients with Fibrinogen Defects | Elvira Grandone | ![]() |
![]() |
|||
PB-293 | Increased Fibrinolysis as a Specific Marker of Poor Outcome after Cardiac Arrest | Michael Schwameis | ![]() |
![]() |
|||
PB-295 | Euglobulin Lysis Time (ELT) Behaviour in Patients Wwith Abnormal Clot Solubility Test (CST) | Lucia Remotti | ![]() |
![]() |
|||
PB-296 | Association between Use of Recombinant Tissue Plasminogen Activator and In-hospital Mortality and 30-day Readmission among Ischemic Stroke Patients Undergoing Mechanical Thrombectomy: A Retrospective Cohort Study | Joshua Brown | ![]() |
![]() |
|||
PB-297 | Staphylokinase Potentiates Thrombolytic Effect of Single Chain Pro-urokinase in Plasma Milleu in vitro | Roza Aisina | ![]() |
![]() |
|||
PB-298 | Local Ultrasound-facilitated Thrombolysis in Pulmonary Embolism: First Dutch Experience and Retrospective Comparison with Systemic Thrombolysis | Maria Adriana de Winter | ![]() |
![]() |
|||
PB-302 | Clot Formation Assessment in Septic Patients with Cancer using a Time-based Parameter from the ROTEM Velocity Curves. A Prospective Observational Pilot Study | Ecaterina Scarlatescu | ![]() |
![]() |
|||
PB-303 | Increase in Plasma Stability and Thrombolytic Efficacy of pro-UK by Chemical Modification of its Arginine Residues | Liliya Mukhametova | ![]() |
![]() |
|||
PB-307 | Gender Differences in TAFI Regulation in Some Disorders | Eugene Roitman | ![]() |
![]() |
|||
PB-309 | The Role of Plasminogen Activator Inhibitor-1 (PAI-1) Levels and PAI-1 4G/5G Polymorphism in the Outcome of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients | Zsuzsa Bagoly | ![]() |
![]() |
|||
PB-314 | Different Pattern of Platelet Binding to Monocytes in Healthy Volunteers and in Patients with Coronary Artery Disease | Marina Loguinova | ![]() |
![]() |
|||
PB-315 | Pharmacological Actions of Inosine in a Hypercholesterolemic Model: Is It a New Antiatherosclerotic Drug? | Gabriel Ferreira Lima | ![]() |
![]() |
|||
PB-316 | Cement Dust Exposure Associated with Anaemia, Increased Platelets, Cardiac Markers and Dyslipidamia among Male Cement Workers in Calabar, Nigeria | Ifeyinwa Maryann Okafor | ![]() |
![]() |
|||
PB-317 | Hyperhomocysteinemia and endothelial Dysfunction of the Athletes in the Arctic Region | Nadezda Vorobyeva | ![]() |
![]() |
|||
PB-318 | Folate Deficiency of the Nenets of the Arctic Regions of the Russia | Nadezda Vorobyeva | ![]() |
![]() |
|||
PB-322 | Recombinant Human Soluble Thrombomodulin Protects Vascular Endothelial Cells from Radiation-induced DNA Damage | Takayuki Ikezoe | ![]() |
![]() |
|||
PB-324 | Ubiquitin-driven p38 Inflammatory Signaling Induced by Protease-activated Receptors | Joann Trejo | ![]() |
![]() |
|||
PB-326 | The Anti-coagulant Vitamin K-dependent Factor, Protein S, Alters Endothelium Functions by Regulating Multiple Vascular Permeability Related Signaling Pathways | Omar Benzakour | ![]() |
![]() |
|||
PB-327 | Simultaneous Assessment of sE-Selectin, Platelet Count and Mean Platelet Volume as Biomarkers for Pre-eclampsia | Maha Othman | ![]() |
![]() |
|||
PB-330 | Comparison of Syndecan-1 Levels as a Marker of Endotheliopathy in Thermal Injury and Blunt Trauma | Robert Ball | ![]() |
![]() |
|||
PB-332 | Ceramide 1 Phosphate Protects Human Endothelial Colony Forming Cells from Apoptosis and Increase Their Angiogenic Responses | Hebe Agustina Mena | ![]() |
![]() |
|||
PB-333 | Ticagrelor Induces the Expression of the Endothelial Phenotype CD34+ Progenitor Cells in the Presence of ADP via an Adenosine-mediated Mechanism | Alexandros D. Tselepis | ![]() |
![]() |
|||
PB-334 | Coxsackievirus B3 Replicates in Endothelial Colony Forming Cells and Inhibits Angiogenesis | Paula Romina Zubiry | ![]() |
![]() |
|||
PB-335 | Circulating Progenitor and Mature Endothelial Cells in Patients with Venous Thromboembolic Disease | Sofia Grille | ![]() |
![]() |
|||
PB-337 | PAR-1 Inhibition Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Endotoxemia | Christian Schoergenhofer | ![]() |
![]() |
|||
PB-340 | Type I Interferons Upregulate IFITM3 in Human Platelets and Megakaryocytes to Control Viral Infectivity | Robert Campbell | ![]() |
![]() |
|||
PB-341 | Sphingosine 1-phosphate Induces COX-2/PGE2 Expression via PKCalpha-mediated MAPKs and NF-kappaB Cascades in Human Cardiac Fibroblasts | Chuen-Mao Yang | ![]() |
![]() |
|||
PB-342 | Utility of New Red Cell Parameters for Identifying Functional Iron Deficiency and Anemia in Patients with Familial Mediterranean Fever | Zühre Kaya | ![]() |
![]() |
|||
PB-343 | The Role of Cytokines in the Development of Acquired Aplastic Anemia | Inna Berger | ![]() |
![]() |
|||
PB-346 | Hemoglobin-activated Platelet Regulates Macrophage Polarization under Hemolytic Conditions | Rashi Singhal | ![]() |
![]() |
|||
PB-350 | Circulating Cholesterol Containing, Platelet-derived Microparticles Contribute to the Procoagulant State Observed in Systemic Lupus Erythematosus | Shuaishuai Hu | ![]() |
![]() |
|||
PB-352 | Circulating Microparticles Improve Thrombin Generation and Fibrin Formation in Factor VIII Deficiency Plasma | Jovan Antovic | ![]() |
![]() |
|||
PB-356 | Delayed Initiation and Inadequate Anticoagulation as Independent Risk Factors for Development of Post Thrombotic Syndrome (PTS) - An Observational Study from a Tertiary Care Hospital in North India | Vikas Suri | ![]() |
![]() |
|||
PB-357 | Mitofusin 2 Regulates Mitochondria in Megakaryocytes, and Hemostasis and Thrombosis in Mice | Jesse W. Rowley | ![]() |
![]() |
|||
PB-358 | PDK1 Is Crucial to Pro-platelet Formation and Thrombopoiesis by Regulating MK Actin Polymerization | Sascha Geue | ![]() |
![]() |
|||
PB-359 | Unique Megakaryocytes from Human Adipose-derived Mesenchymal Stromal/stem Cell Line: Comparison with Hematopoietic Stem Cell-derived Megakaryocytes | Yukako Ono-Uruga | ![]() |
![]() |
|||
PB-360 | Nucleic Acid-based Therapeutic Targets for Protein S Deficient Patients | Ross Baker | ![]() |
![]() |
|||
PB-361 | Structural Insights during the Recognition of Endothelial Cell Protein C Receptor to the Protein C/activated Protein C in Presence of Phospholipid within EPCR Groove | Ramesh Prasad | ![]() |
![]() |
|||
PB-362 | Retrospective Study about using Bridging Therapy with Sodium Bemiparin in our Center | Pablo Romero Garcia | ![]() |
![]() |
|||
PB-364 | Betrixaban: Impact on Routine and Specific Coagulation Assays - A Practical Laboratory Guide | Romain Siriez | ![]() |
![]() |
|||
PB-366 | Inhibition of Factor XII is Antithrombotic in a Primate Model of Extracorporeal Membrane Oxygenation | Michael Wallisch | ![]() |
![]() |
|||
PB-367 | Effects of SERPINC1, PROC, PROS1 and EPCR Polymorphisms on the Risk of Venous Thromboembolism and Myocardial Infarction in Young Individuals | Zsuzsanna Bereczky | ![]() |
![]() |
|||
PB-368 | Structural and Functional Study of Naringin Octasulfate (NOS) on Human Antithrombin and Probing its Role in Thrombus Reduction using Rat Model | Irshad Ahmad | ![]() |
![]() |
|||
PB-372 | Emicizumab Impact on Factor VIII Inhibitor Determination in Plasma Samples from Persons with Hemophilia A (PwHA) using a New Kit for Modified Nijmegen-Bethesda Assay (MNBA) | Ali Sadeghi-Khomami | ![]() |
![]() |
|||
PB-375 | Data of Real-life Anticoagulant Treatment with Edoxaban In Patients with Atrial Fibrillation and Patients with Secondary Prevention of Deep Vein Thrombosis. Experience of Thirteen Months in our Center | Almudena Garcia Ruiz | ![]() |
![]() |
|||
PB-376 | Cross-sectional Survey of Minor Bleeding Rates in Children Prescribed Warfarin | Nadia Poci | ![]() |
![]() |
|||
PB-377 | Antithrombin Levels in Nigerians with Type2 Diabetes | Omolade Augustina Awodu | ![]() |
![]() |
|||
PB-378 | Laboratory Algorithm of Diagnostic of Hemorrhagic Diseases in Patients with Isolated Prolonged Activated Partial Thromboplastin Time (APTT) | Valeriia Krasivska | ![]() |
![]() |
|||
PB-379 | From Tissue Factor to Thrombin to Fibrin under Whole Blood Flow: Thrombin Makes Fibrin but Fibrin Quenches Thrombin | Scott Diamond | ![]() |
![]() |
|||
PB-380 | Effect of Andexanet-tissue Factor Pathway Inhibitor (TFPI) Interaction on in vitro Clot Formation and Lysis via Different Coagulation Pathways | Genmin Lu | ![]() |
![]() |
|||
PB-382 | Molecular Sequencing of Factor VII Variants through Collaborative Advocacy for Families in the United States: 154 Individuals Using Multi-gene Next Generation Panel | Diane Nugent | ![]() |
![]() |
|||
PB-383 | Inappropriate Use of Fresh Frozen Plasma in a Tertiary Care Hospital | Sidra Asad Ali | ![]() |
![]() |
|||
PB-385 | Clot Waveform Analysis: Determination of Optimal Wavelength to Assess the Fibrin Coagulation Process | Jonathan Evrard | ![]() |
![]() |
|||
PB-387 | Coagulation Abnormalities and Risk Assessment in Acute Promyelocytic Leukemia - An Experience fom Resource Constraint Country | Nida Anwar | ![]() |
![]() |
|||
PB-389 | eNOS, ACE AND PAI-1 Gene Polymorphisms in a Sample of General Population of Northern Greece | Androniki Papoutsi | ![]() |
![]() |
|||
PB-391 | Association between Factor V Leiden and APCR Values: Data from a Portuguese University Hospital | Analia Carmo | ![]() |
![]() |
|||
PB-393 | Prevalence of Common Genetic Variants Associated with Thrombophilia in Asymptomatic young Individuals with a Family History of Thrombosis | Androniki Papoutsi | ![]() |
![]() |
|||
PB-394 | Identification and Differentiation of Coagulation Factors in Prothrombin Complex Concentrates (PCC´s) | Maurice Mandago | ![]() |
![]() |
|||
PB-398 | FXIa Binds and Forms a Complex with Plasminogen Activator Inhibitor-1 that Inhibits Its Activity and Induces Internalization and Degradation by Endothelial Cells | Anh Ngo | ![]() |
![]() |
|||
PB-402 | Saliva-derived Tissue Factor Induces Thrombin Generation in a Diurnal Rhythm | Lisa N. van der Vorm | ![]() |
![]() |
|||
PB-403 | Activated Factor VII Fused with Transferrin Showed Prolonged Half-life with Safe Toxicity Profile in Animal Models | InYoung Song | ![]() |
![]() |
|||
PB-404 | "Real World" Usage of Prothrombin Complex Concentrates (PCCs) to Correct Coagulopathy. A 3 Year Retrospective Review in an Academic Hospital System | Ismini Kourouni | ![]() |
![]() |
|||
PB-405 | Gene Expression of Coagulation Factors after Experimental Snake Envenomation in Mice | Marcelo Larami Santoro | ![]() |
![]() |
|||
PB-406 | Enhanced FIX Collagen IV Binding Shows Improved Hemostatic Effects in a Hemophilia B Mouse Model | Davide Matino | ![]() |
![]() |
|||
PB-408 | Factor XI Level Is a Determinant of Plasma Clot Growth | Cornelis Kluft | ![]() |
![]() |
|||
PB-409 | Robustness of Spatial Thrombin Generation and Fibrin Clot Propagation | Anna Kuprash | ![]() |
![]() |
|||
PB-410 | The Blood Clot is Covered by a Fibrin Film that Protects against Microbes | Fraser Macrae | ![]() |
![]() |
|||
PB-411 | Binding of Coagulation Factor XIII Zymogen to Activated Platelet Subpopulations: Roles of Integrin aIIbß3 and Fibrinogen | Nadezhda Podoplelova | ![]() |
![]() |
|||
PB-412 | Presence and Function of Cellular Factor XIII in Human Cornea | Zsuzsanna Z. Orosz | ![]() |
![]() |
|||
PB-413 | The Effect of Factor XIII Levels on the Incorporation of a2-plasmin Inhibitor into Fibrin Clots: Association with the Therapeutic Outcome of Acute Ischemic Stroke Patients | Zsuzsa Bagoly | ![]() |
![]() |
|||
PB-415 | Fibrin Fiber Mechanical and Structural Properties Are Altered in Individuals with Cardiovascular Disease on Low/Medium Dose Aspirin | Martin Guthold | ![]() |
![]() |
|||
PB-416 | Factor XIII Concentrate Can Improve Clot Stabilization Guided by Thromboelastometry in Patient with Liver Disease: A Case Report | Tomaz Crochemore | ![]() |
![]() |
|||
PB-418 | Plasma Fibrinogen Concentration As an Acute Marker of Myocardial Infarction | Chinedu Kingsley Dike | ![]() |
![]() |
|||
PB-419 | Apixaban Does Not Generate False-positive dRVVT Interpretations for Lupus Anticoagulants, Even at Peak Levels | Osamu Kumano | ![]() |
![]() |
|||
PB-422 | Antiphospholipid Syndrome: Maternal and Perinatal Outcome after Treatment in Next Pregnancy. Retrospective Analysis | Beatriz Grand | ![]() |
![]() |
|||
PB-423 | Are IgM Antiphospholipid Antibodies Redundant in the Classification Criteria for the Antiphospholipid Syndrome? | Walid Chayoua | ![]() |
![]() |
|||
PB-424 | A Single-arm Pilot Feasibility Cohort Study of Rivaroxaban in Antiphospholipid Syndrome | Mark Crowther | ![]() |
![]() |
|||
PB-426 | Use of Direct Oral Anticoagulant in Antiphospholipid Syndrome: Systematic Review of Literature | Denis Wahl | ![]() |
![]() |
|||
PB-431 | Evaluation of Lupus Anticoagulant Testing: A Descriptive Single Centre Experience | Sergio Felipe Pinzon Mariño | ![]() |
![]() |
|||
PB-433 | A Comparison between Mixing Test Specific Cut-off and the Index of Circulating Anticoagulant with Multiple APTT and dRVVT in Specificity for Lupus Anticoagulant | Osamu Kumano | ![]() |
![]() |
|||
PB-434 | Thrombotic Risk Assessment in Antiphospholipid Syndrome | Analia Carmo | ![]() |
![]() |
|||
PB-436 | Recent Metods for Laboratory Detection of Lupus Anticoagulant in Patients with Antiphospholipid Syndrome | Valeriia Krasivska | ![]() |
![]() |
|||
PB-439 | Direct Oral Anticoagulants in Venous Thromboembolic Disease; Boon or Bane? | Andrea Ang | ![]() |
![]() |
|||
PB-440 | Outcomes in Non-valvular Atrial Fibrillation Patients with Good and Poor INR Control after Switching to Direct Oral Anticoagulants | Scott Kaatz | ![]() |
![]() |
|||
PB-441 | PK/PD (Thrombinography and Fibrinography) Response Variability to Rivaroxaban in Patients Aged 80 Years and Older with Atrial Fibrillation: Results of the ADAGE Study | Geoffrey Foulon | ![]() |
![]() |
|||
PB-442 | Health-related Quality of Life after Pharmacomechanical Catheter-directed Thrombolysis for Proximal Deep Vein Thrombosis | Susan R. Kahn | ![]() |
![]() |
|||
PB-443 | DTI/DXI Interferences with Global Coagulation Tests in Daily Care Emergency Admissions - Results of the Prospective DRESDEN NOAC REGISTRY (NCT01588119) | Jan Beyer-Westendorf | ![]() |
![]() |
|||
PB-444 | Evaluation of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of the Anti-factor XI Antibody, AB023, in Healthy Adult Volunteers | Christina U. Lorentz | ![]() |
![]() |
|||
PB-445 | The Indirect Effects of Dabigatran En Rivaroxaban on Fibrinolysis | Suzanne Zwaveling | ![]() |
![]() |
|||
PB-446 | Risk of Thrombosis and Bleeding in Patients Treated with Warfarin or Apixaban for Non-valvular Atrial Fibrillation: A Large, National, Retrospective Study | Matthew Wanat | ![]() |
![]() |
|||
PB-447 | Novel Universal Antidote to Non-Vitamin K Antagonist Anticoagulants | Georges Jourdi | ![]() |
![]() |
|||
PB-448 | Comparing the Proportions of Patients that Meet Criteria for Extended Prophylaxis with Betrixaban Based on APEX Trial and FDA Indication | Scott Kaatz | ![]() |
![]() |
|||
PB-449 | Reversal of Direct Factor Xa Inhibitor-Associated Major Bleeding with Four-factor Prothrombin Complex Concentrate: A Systematic Review and Meta-analysis | Siavash Piran | ![]() |
![]() |
|||
PB-450 | Resumption of Anticoagulant Therapy after Anticoagulant-Related Gastrointestinal Bleeding: A Systematic Review and Meta-analysis | Derek Little | ![]() |
![]() |
|||
PB-452 | Recurrent Thrombosis in Patients with Antiphospholipid Antibodies Treated with Vitamin K Antagonists or Rivaroxaban | Maria Abbattista | ![]() |
![]() |
|||
PB-454 | Variable Response in Individuals to Rivaroxaban and Apixaban over Time | Suzanne Zwaveling | ![]() |
![]() |
|||
PB-455 | Effect of Anti-arrhythmic Medication Drug Interactions on Thrombotic and Bleeding Outcomes in Patients with Atrial Fibrillation | Matthew Wanat | ![]() |
![]() |
|||
PB-456 | Lean Body Weight is the Best Scale for Venous Thromboprophylaxis Algorithm in Severely Obese Patients Undergoing Bariatric Surgery | Corinne Frere | ![]() |
![]() |
|||
PB-458 | Post Analytical External Quality Assessment of Anticoagulant Dosing for Warfarin Therapy | Dianne Kitchen | ![]() |
![]() |
|||
PB-459 | Creation of an Algorithm for Predicting Doses of Warfarin < 17.5mg Using CYP2C9 and VKORC1 Polymorphisms and Non-genetic Factors | Maria Auxiliadora Parreiras Martins | ![]() |
![]() |
|||
PB-460 | Warfarin Use Increases Bleeding Risk in Hemodialysis Patients with Atrial Fibrillation: Evidence from Meta-analysis Using Real World Data | Salman Hussain | ![]() |
![]() |
|||
PB-461 | Change of Rivaroxaban Anticoagulant Effect during the 24 Hours | Olesya Matvienko | ![]() |
![]() |
|||
PB-463 | Flow Based Analysis of Heparin Inhibition of VWF Dependant Platelet Capture | Amita Ranger | ![]() |
![]() |
|||
PB-465 | Real-world Experience of Direct Oral Anticoagulants Use in North Melbourne, Australia | Hui Yin Lim | ![]() |
![]() |
|||
PB-466 | Relationship between Dabigratan Concentrations in Plasma and Results of Routine Coagulation Assays PT, APTT, TT and Fibrinogen | Sandra Margetic | ![]() |
![]() |
|||
PB-467 | Measuring Anti-factor Xa Levels to Monitor Enoxaparin in Pregnant Women: A Prospective Comparative Study | Fahad Aleidan | ![]() |
![]() |
|||
PB-468 | Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation in Clinical Practice: Outcomes from the First Observational and Prospective Study in Spanish Population | Maria Cerdá Sabater | ![]() |
![]() |
|||
PB-470 | Multihospital System Implementation of the Anti-Xa for Titration for Monitoring Unfractionated Heparin (UH) Therapy | Paul Lindholm | ![]() |
![]() |
|||
PB-471 | Correcting Inappropriate Prescribing of Direct Oral Anticoagulants: A Population Health Approach | Geoffrey Barnes | ![]() |
![]() |
|||
PB-472 | Impact of Rivaroxban on Platelet Reactivity and von Willebrand Factor Antigen and Activity in Patients with Venous Thrombosis | Nina Schultz | ![]() |
![]() |
|||
PB-473 | Weekly Warfarin Maintenance Dose According to Variations in Four Genes Evaluated in Patients Assisted at a Brazilian Anticoagulation Clinic | Maria Auxiliadora Parreiras Martins | ![]() |
![]() |
|||
PB-477 | Development, Implementation and Evaluation of Application for Monitoring Oral Anticoagulant Therapy | Maria Auxiliadora Parreiras Martins | ![]() |
![]() |
|||
PB-479 | A Multicenter Experience with Idarucizumab "in Real World" as Reversal Anticoagulation of Dabigatrán | Marta Villalba Montaner | ![]() |
![]() |
|||
PB-481 | Retrospective Observational Study of Patients Treated with Rivaroxaban in Saudi Arabia | Muhammad Riazuddin | ![]() |
![]() |
|||
PB-483 | Description and Evaluation of the Comparison of Activated Partial Thromboplastin Time versus Anti-factor Xa Activity for Therapeutic Unfractionated Heparin Monitoring in a Tertiary Academic Medical Center using Three Different Adult Weight-based, Nurse Ma | Laura Talamo | ![]() |
![]() |
|||
PB-484 | Idarucizumab for Reversing Anticoagulation in Patients Treated with Dabigatran: Experience in our Center | Estefania Morente Constantin | ![]() |
![]() |
|||
PB-485 | Warfarin Dose Requirements in Patients with Heart Diseases Assisted at an Anticoagulation Clinic in the Southeast Brazil | Maria Auxiliadora Parreiras Martins | ![]() |
![]() |
|||
PB-486 | Direct-acting Oral Anticoagulant Drug Level Monitoring in Clinical Patient Management | Batia Roth | ![]() |
![]() |
|||
PB-487 | Establishment of a Centralized Monitoring System for Patients Receiving Anticoagulant Therapy in the Arkhangelsk Region Russia | Nadezda Vorobyeva | ![]() |
![]() |
|||
PB-488 | Evaluation of Algorithms for Warfarin Dose Prediction | Maria Auxiliadora Parreiras Martins | ![]() |
![]() |
|||
PB-489 | Development of an Educational Intervention Focused on Low-income Population Treated with Warfarin | Maria Auxiliadora Parreiras Martins | ![]() |
![]() |
|||
PB-491 | Direct Oral Anticoagulant Use in Obese Patients: Preliminary Results of a Pilot Study | Laura Talamo | ![]() |
![]() |
|||
PB-492 | Arterial Thrombosis Depends on Shear Rate More Than Shear Rate Gradient | David Ku | ![]() |
![]() |
|||
PB-493 | Increased Platelet Count and Reticulated Platelets in Recently Symptomatic versus Asymptomatic Carotid Artery Stenosis and in Cerebral Microembolic Signal-negative Patient Subgroups: Results from the HEIST Study | Stephen Murphy | ![]() |
![]() |
|||
PB-495 | Significance of Single Nucleotide Polymorphisms (SNPs) within Genes Encoding Platelet Glycoprotein Receptors in Patients with Infective Endocarditis (IE) | Mariia Sorokina | ![]() |
![]() |
|||
PB-496 | Risk Factors for Brain Vessels´s ?hrombosis/Stenosis in Young Patients with Ischemic Stroke | Tsvetomir Tsvetanov | ![]() |
![]() |
|||
PB-497 | In vitro Effects of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells Survival and Functions | Jonathan Douxfils | ![]() |
![]() |
|||
PB-500 | Resonance Raman Spectroscopy as a Tool to Study Blood Flow in Brain Vessels in vivo | Evelina I. Nikelshparg | ![]() |
![]() |
|||
PB-501 | Assessing Three-dimensional Fibrin Polymerization Dynamics during Heparin Administration and Protamine Reversal in Cardiac Surgical Patients | Diane Malu Tshikudi | ![]() |
![]() |
|||
PB-503 | Ir-CPI: An Original Inhibitor of Thrombosis and Thrombosis-associated with Cancer | Edmond Godfroid | ![]() |
![]() |
|||
PB-505 | Effectiveness and Safety of Rivaroxaban versus Low Molecular-weight Heparin for Treatment of Cancer-associated Thromboembolism | Craig I. Coleman | ![]() |
![]() |
|||
PB-506 | Optimizing Therapy for Venous Thromboembolism in Multiple Myeloma: A Systematic Review | Samuel Abegunde | ![]() |
![]() |
|||
PB-508 | Comparative Efficacy and Safety of Anticoagulation for the Treatment of Cancer-associated Thrombosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials | Craig I Coleman | ![]() |
![]() |
|||
PB-509 | A Monoclonal Antibody to Human Podoplanin Inhibits Human Platelet Aggregation Induced by Tumor Cells | Yiming Zhao | ![]() |
![]() |
|||
PB-510 | D-dimer Levels for Prediction of Symptomatic Central Venous Catheter-related Thrombosis in Breast Cancer Patients | Ilham Benzidia | ![]() |
![]() |
|||
PB-511 | Hypercoagulation Screening as Tool for Cancer Diagnosis: An Update on Tumor Incidence and Risk Factors in the HYPERCAN Study | Sara Gamba | ![]() |
![]() |
|||
PB-513 | Cost-effectiveness of Edoxaban versus Dalteparin for Treatment of Cancer-associated Thrombosis | Nathan Connell | ![]() |
![]() |
|||
PB-514 | Non-phosphorylated and Phosphorylated Signal Transduction Peptide (STP) of Tissue Factor (TF) in Urine Are Potential Biomarkers for Bladder and Colon Cancer | Robert Greenfield | ![]() |
![]() |
|||
PB-516 | Leucocyte and Platelet Activation in Patients with BCR-ABL Negative Myeloproliferative Disorders | Charlene Portelli | ![]() |
![]() |
|||
PB-519 | Evaluation of Risk Factors and Assessment Models for Predicting Venous Thromboembolism in Lung Cancer Patients | Joanna Rupa-Matysek | ![]() |
![]() |
|||
PB-520 | Splanchnic Thrombosis Associted to Myeloproliferative Neoplasms: A Cohort of 233 Tunisian Patients | Hadef Skouri | ![]() |
![]() |
|||
PB-521 | The Effect of Hydroxyurea on Blood Coagulation in Sickle Cell Disease | Munira Borhany | ![]() |
![]() |
|||
PB-522 | The Effect of Inflammatory Cytokines IL-6, IL-10, IL-1b and TNFa on Thromboelastography Parameters in Pediatric Patients with Acute Lymphoblastic Leukemia | Saskia Prasca | ![]() |
![]() |
|||
PB-524 | Clinical and Global Hemostatic Parameters in Patients with JAK2 V617F Mutation Myeloproliferative Neoplasms (MPNs) | Aimwipa Sasakul | ![]() |
![]() |
|||
PB-525 | Generation of Neo-epitopes on Hypochlorous Acid-modified Human Antithrombin: An Immunological Study | Parvez Ahmad | ![]() |
![]() |
|||
PB-527 | The Usefulness of Standard and Derived ROTEM Parameters for DIC Prediction in Septic Patients | Ecaterina Scarlatescu | ![]() |
![]() |
|||
PB-528 | Recombinant A2 Domain of von Willebrand Factor Attenuates Microthrombi Formation, Organ Injuries and D-dimer Levels in a Porcine Model of Methicillin-resistant Staphylococcus Aureus (MRSA) Sepsis-induced Disseminated Intravascular Coagulation (DIC) | Miguel Cruz | ![]() |
![]() |
|||
PB-529 | The Expression of Tissue Factor between Monocyte Subsets: A Role in Sepsis-associated Coagulopathy? | Kathryn Mary Musgrave | ![]() |
![]() |
|||
PB-530 | Added Value of the DIC Score and of D-dimer to Predict Outcome after Successfully Resuscitated Out-of-Hospital Cardiac Arrest | Nina Buchtele | ![]() |
![]() |
|||
PB-532 | Evaluation of the Effectiveness of AT III Concentrate in Acute DIC-syndrome | Nadezda Vorobyeva | ![]() |
![]() |
|||
PB-533 | von Willebrand Factor Interactions with Platelets and Leukocytes is Critical for Obesity-mediated Venous Thrombosis | Alison Michels | ![]() |
![]() |
|||
PB-534 | Iron Deficiency Increases Platelet Procoagulant Capacity in a Ferric Chloride Model of Arterial Thrombosis | Kristine Jimenez | ![]() |
![]() |
|||
PB-541 | A Highly Efficient and Adhensive Antibacterial Dextran Derivative for Rapid Hemostasis with Wound Healing | Chunyu Liu | ![]() |
![]() |
|||
PB-543 | Normal to High Anti-Xa Levels in High Body Weight Patients Using Apixaban and Rivaroxaban | Zahra Mahir | ![]() |
![]() |
|||
PB-544 | Global Coagulation Assay Changes in Patients with Chronic Renal Impairment | Hui Yin Lim | ![]() |
![]() |
|||
PB-545 | Assessment of the Agreement between the International Normalised Ratio (INR) Values Obtained by Applying Two Different Reagent/Instrument Combinations | Alicia Noemi Blanco | ![]() |
![]() |
|||
PB-547 | The Coagulation System State in Patients with Philadelphia-negative Myeloproliferative Neoplasms | Olesya Matvienko | ![]() |
![]() |
|||
PB-548 | Thromboelastographic Changes in Patients with BCR-ABL Negative Myeloproliferative Disorders | Marie Claire Cini | ![]() |
![]() |
|||
PB-549 | The Impact of Age, Ethnicity and Gender on Global Coagulation Assays | Hui Yin Lim | ![]() |
![]() |
|||
PB-551 | Identification of Protein C System-associated Thrombophilia using an Endothelial Cell-based Thrombin Generation Assay | Ali Amirkhosravi | ![]() |
![]() |
|||
PB-554 | A Rapid Fully-automated Chemiluminescent Immunoassay for the Early Quantification of ADAMTS13 Activity in TTP Diagnosis | Carla Valsecchi | ![]() |
![]() |
|||
PB-555 | Urgent Laboratory Investigation of HIT Syndrome with an Automated Immunoassay in Cardiovascular Patients | Theodora Kostelidou | ![]() |
![]() |
|||
PB-556 | Platelet Hyporeactivity Combined with Enhanced Coagulation in Healthy Term and Preterm Newborns During First Days of Life | Ekaterina Koltsova | ![]() |
![]() |
|||
PB-557 | Von Willebrand Factor Antigen Levels Predict Major Adverse Cardiovascular Events in Patients with Asymptomatic Carotid Stenosis | Katarina D. Kovacevic | ![]() |
![]() |
|||
PB-558 | Thrombin Generation in Real-world Patients Treated with Two Different Doses of Apixaban | María De Lourdes Herrera | ![]() |
![]() |
|||
PB-560 | Active von Willebrand Factor Levels in Kidney Disease Are Associated with Disease Severity and Type of Dialysis | Lisa N. van der Vorm | ![]() |
![]() |
|||
PB-561 | Role of Thromboelastography to Assess Thrombin Generation in Acute Coronary Syndrome (ACS) | Qiuya Lu | ![]() |
![]() |
|||
PB-563 | Laboratory Assessment of Dabigatran Levels and Anti-Xa Anticoagulant Levels | Ivanka Paskaleva | ![]() |
![]() |
|||
PB-566 | Natural Anticoagulant Deficiencies in Thais: A Population-based Study | Ponlapat Rojnuckarin | ![]() |
![]() |
|||
PB-567 | Changes in Tissue Factor Concentration and APTT in Haemolysed and Non-haemolysed Paired Citrate Samples | Kieron Hickey | ![]() |
![]() |
|||
PB-569 | DOAC Filter Effect on Thrombin Generation: Pre-analytical Considerations and Analytical Perspectives | Damien Gheldof | ![]() |
![]() |
|||
PB-570 | Heparin-induced Thrombocytopenia: An International Assessment of the Quality of Laboratory Testing | Zachary Liederman | ![]() |
![]() |
|||
PB-571 | A Comparison of Two Point-of-Care Testing Platforms (Coaguchek® Pro II and Coaguchek® INRange) to Standard Laboratory Measurement of the International Normalised Ratio | Shu Hui Yeang | ![]() |
![]() |
|||
PB-572 | Measurement of Coagulation Factors during Rivaroxaban and Apixaban Treatment: Results from Two Crossover Trials | Luuk J.J. Scheres | ![]() |
![]() |
|||
PB-573 | Stability of Thrombin Generation and Thrombin Dynamics in Healthy Individuals over a One-year Period | Joke Konings | ![]() |
![]() |
|||
PB-574 | The Association of Hereditary Thrombophilia with Clinically Relevant Hypercogulation State and Free Flap Thrombosis in Microvascular Surgery | Karina Drizlionoka | ![]() |
![]() |
|||
PB-575 | Use of a Liquid Recombinant Thromboplastin (DG-PT RecombiLIQ, Diagnostic Grifols) for Monitoring Vitamin K Antagonist Therapy | Anita Woolley | ![]() |
![]() |
|||
PB-576 | Heparin Anti-Xa Assay versus Activated Partial Thromboplastin Time to Monitor Unfractionated Heparin during Extracorporeal Membrane Oxygenation | Deepa Jayakody Arachchillage | ![]() |
![]() |
|||
PB-577 | An Automated Modified Anti-Xa Assay for the Potency Assessment of Bemiparin in Pharmaceutical Formulations | Alejandra Scazziota | ![]() |
![]() |
|||
PB-580 | Limits to Sensitivity of 4T Score for Heparin Induced Thrombocytopenia | Deepa Jayakody Arachchillage | ![]() |
![]() |
|||
PB-581 | External Quality Assessment of Point of Care Testing in Haemostasis | Shelene Munroe-Peart | ![]() |
![]() |
|||
PB-582 | Clot Waveform Analysis for Measuring and Quantifying Fibrin Clot Formation | Jonathan Evrard | ![]() |
![]() |
|||
PB-583 | The Calibrated Automated Thrombography in Patients with Factor XII Deficiency | Natalya Silina | ![]() |
![]() |
|||
PB-584 | Thrombin Generation Analysis with a New Automated System (ST-Genesia): Inter-series Performances during DRIVING Study and Comparison with CAT System | Virginie Siguret | ![]() |
![]() |
|||
PB-586 | D-dimer Measurement: Lipid Interference Removal through High-speed Centrifugation | Audrey Carlo | ![]() |
![]() |
|||
PB-588 | Development of a HPLC-UV Method for the Measurement of Dabigatran from Plasma and its Application as Reference Method for the Evaluation of a Novel Chromogenic Dabigatran Assay | Anita Kuruczné Kern | ![]() |
![]() |
|||
PB-589 | Fibrinolysis System and Combined oral Contraceptives | Nadezda Vorobyeva | ![]() |
![]() |
|||
PB-591 | Reference Change Value for INR: A Simple Tool for Management of Patients on Oral Anticoagulation | Alejandra Scazziota | ![]() |
![]() |
|||
PB-593 | Reproducibility of Rotem® Device | Erica Scalambrino | ![]() |
![]() |
|||
PB-594 | Taipan Snake Venom Time Detects the Lupus Anticoagulants in Anticoagulated, Triple-positive Antiphospholipid Syndrome Patients | Gary William Moore | ![]() |
![]() |
|||
PB-596 | Improving Lupus Anticoagulant Testing with 2 New APTT and dRVVT Reagents | Corinne Frere | ![]() |
![]() |
|||
PB-598 | Validation of an Automated Algorithm for Interpretation of Lupus Anticoagulant Testing on Stago STA-R Max | Lisa Florin | ![]() |
![]() |
|||
PB-599 | Thrombin Generation Test in Detection of Prothrombotic Phenotype in Asymptomatic Carriers of the FV G1691A or/and FII G20210A Mutations | Olesia Matvienko | ![]() |
![]() |
|||
PB-600 | Management of Direct Oral Anticoagulants for Low-bleeding Risk Surgery: The Example of Cataract Surgery | Anne Godier | ![]() |
![]() |
|||
PB-601 | Using Drug Levels to Guide Peri-operative Management of Direct Oral Anticoagulants Prior to Emergency Orthopaedic Surgery; Experience from a Large Teaching Hospital within the UK | Emily Millen | ![]() |
![]() |
|||
PB-603 | Antithrombin Levels Less than 60% Lead to Reduced Anti-Xa Levels | Claire Pillion | ![]() |
![]() |
|||
PB-605 | Inpatient to Outpatient Transition of Care for Pediatric Patients with Venous Thromboembolism | James Munn | ![]() |
![]() |
|||
PB-606 | Cerebral Sinovenous Thrombosis (CSVT) in Children: 25 Years Single-center Prospective Pediatric Cohort in Argentina | Gabriela Sciuccati | ![]() |
![]() |
|||
PB-607 | Significance of GPIba -5T>C, GPIba VNTR, GPVI T13254C Polymorphisms and HPA-2 in the Etiology of Pediatric Arterial Ischemic Stroke | Desiree Coen Herak | ![]() |
![]() |
|||
PB-610 | D Dimer Levels and Thrombosis in Children with Systemic Lupus Erythematosus | Jasmina Ahluwalia | ![]() |
![]() |
|||
PB-611 | Anti-factor H Autoantibody-associated Hemolytic Uremic Syndrome in an Argentinean Pediatric Cohort | Célia Dos Santos | ![]() |
![]() |
|||
PB-613 | Prosthetic Valve Thrombosis in Children | Patricia Kewada | ![]() |
![]() |
|||
PB-614 | Towards a Consensus for Standardized Assessment of Pediatric Patients with Vascular Malformations (VM) at Risk for Coagulopathy | Leonardo Brandao | ![]() |
![]() |
|||
PB-616 | Dosing, Safety and Efficacy of Therapeutic and Prophylactic Low Molecular Weight Heparin in the Pediatric Population: A Systematic Review | Irene Lisette Maria Klaassen | ![]() |
![]() |
|||
PB-617 | Exploring Adolescent´s Perceptions and Emotional Reaction to Thrombosis and Anti-coagulant Therapy: A Qualitative Study | Tina Biss | ![]() |
![]() |
|||
PB-621 | How do Adolescents Experience Anticoagulant Adherence? A Qualitative Exploration of the Barriers and Facilitators | Kay Anne Rooney | ![]() |
![]() |
|||
PB-624 | Spontaneous Thrombosis in a Patient With Factor XI Deficiency Homozygous for the p.Cys398Tyr Mutation | Utku Aygüne | ![]() |
![]() |
|||
PB-626 | The Joint Effect between Different Types of Combined Oral Contraceptives and Genetic Risk Factors on Venous Thrombosis Risk: Results from the MEGA Case-control Study | Deeksha Khialani | ![]() |
![]() |
|||
PB-627 | Risk of Recurrent Venous Thromboembolism in Pregnancy and Postpartum Period: Results from the MEGA Follow-up Study | Luuk J.J. Scheres | ![]() |
![]() |
|||
PB-628 | Misuse of Low Molecular Heparin in Pregnancy | Julija Samonikov Tosevska | ![]() |
![]() |
|||
PB-629 | Written Alert System Improves Thromboprophylaxis Compliance in Caesarean Women | Cecilia Guillermo | ![]() |
![]() |
|||
PB-631 | Management of Venous Thromboembolism (VTE) during Pregnancy and Post-partum: Findings from the Indian Subset of an International, Observational Study (SAVE) | Ravi Mohan Tiwari | ![]() |
![]() |
|||
PB-632 | Thrombin Generation and Adverse Pregnancy Outcomes | Irina Gribkova | ![]() |
![]() |
|||
PB-634 | Reduced Protein C Global Assay Level in Infertile Women with IVF Failure: A Pilot Study | Hanan azzam | ![]() |
![]() |
|||
PB-635 | Hereditary Thrombophilia Assessment in Pregnancy | Tatjana Makarovska Bojadzieva | ![]() |
![]() |
|||
PB-636 | Localization and Massiveness of Thrombosis in Women with Pregnancy Related Thrombosis Compared to Women with Unprovoked Venous Thromboembolism | Predrag Miljic | ![]() |
![]() |
|||
PB-637 | Prospective Study of Changes in Haemostasis in High-risk Pregnancy | Lucia Stanciakova | ![]() |
![]() |
|||
PB-638 | Risk Assessment of Venous Thromboembolism (VTE) during Pregnancy and Post-partum: Findings from the Indian Subset of an International, Observational Study (SAVE) | Ravi Tiwari | ![]() |
![]() |
|||
PB-639 | Genetic Risk Factors of Endothelial Dysfunction in Pregnant Women | Natalya Silina | ![]() |
![]() |
|||
PB-640 | Characterization and Outcomes of aTTP Patients with Initial or Recurrent Disease: Experience from the Phase III HERCULES Trial of Caplacizumab | Hilde De Winter | ![]() |
![]() |
|||
PB-641 | Efficacy and Safety of Open-label Caplacizumab in Patients with Exacerbations of Acquired Thrombotic Thrombocytopenic Purpura during the Phase III HERCULES Study | Filip Callewaert | ![]() |
![]() |
|||
PB-642 | Treatment of Acquired TTP with the Anti-vWF Nanobody, Caplacizumab, Results in a Significant Reduction in Healthcare Resource Utilization - Data from the Phase III HERCULES Trial | Filip Callewaert | ![]() |
![]() |
|||
PB-644 | Initial Clinical Presentation of Thrombotic Thrombocytopenic Purpura with Focal Stroke: A Series of Patients from the French National Reference Center Registry for Thrombotic Microangiopathies | Maxime Delrue | ![]() |
![]() |
|||
PB-645 | Provision of an External Quality Assessment for ADAMTS13 | Ian Jennings | ![]() |
![]() |
|||
PB-647 | Pre-test Likelihood of ADAMTS13 Severe Deficiency in the Context of Thrombotic Microangiopathies: Validation of the PLASMIC Score in a Southern Italy Hospital | Elvira Grandone | ![]() |
![]() |
|||
PB-648 | "How we Treat": Recurrent TTP Patients Undergoing Elective Surgery | Sara Arcudi | ![]() |
![]() |
|||
PB-652 | Identification of Novel ADAMTS13 Gene Mutation in a Patient with Congenital Thrombotic Thrombocytopenic Purpura | Anila Rashid | ![]() |
![]() |
|||
PB-654 | Evaluation of Hospital Readmissions among Patients Hospitalized for Acute Medical Illness and at Risk for Venous Thromboembolism in the US | Richey Neuman | ![]() |
![]() |
|||
PB-655 | Comparison of the Risk of Recurrence in Patients with Venous Thromboembolism (VTE) Provoked by Major and Minor Surgery and Trauma | Tiago Gregorio | ![]() |
![]() |
|||
PB-656 | Comparative Thrombosis Risk of Vascular Access Devices among Critically Ill Medical Patients | Scott M Stevens | ![]() |
![]() |
|||
PB-657 | Cost-effectiveness of Betrixaban Compared with Enoxaparin for Primary Venous Thromboembolism Prophylaxis in Hospitalised Acute Medically Ill Patients in the United States | Andrea Hafeman | ![]() |
![]() |
|||
PB-658 | Venous Thromboembolism Clinical Risk Assessment Model for Patients with a Lower Limb Trauma Requiring Immobilization: The TIP Score | Pierre-Marie Roy | ![]() |
![]() |
|||
PB-660 | A Single Center Analysis of Pre-, Intra- and Post-operative Thrombotic Events in a Cohort of 470 Orthotopic Whole Liver Transplantations | Nicoletta Riva | ![]() |
![]() |
|||
PB-661 | miRNA Expression Profile in Venous Thrombosis Disease: Results from the Genetic Analysis of Idiopathic Thrombophilia Project | Alba Rodriguez-Rius | ![]() |
![]() |
|||
PB-662 | Clinical Characteristics and Outcome of Patients with Subsegmental Pulmonary Embolism | Farès Moustafa | ![]() |
![]() |
|||
PB-663 | Assessment of General Awareness of Thrombosis and How Best to Communicate this Information | Ann Marie O´Neill | ![]() |
![]() |
|||
PB-664 | Postoperative Venous Thromboembolism Prophylaxis in Perioperative Trials of Tranexamic Acid: A Systematic Review and Meta-analysis | Joshua Taylor | ![]() |
![]() |
|||
PB-665 | Testosterone Therapy and Venous Thromboembolism: A Systematic Review and Meta-analysis | Damon E Houghton | ![]() |
![]() |
|||
PB-666 | Homozygotes in FXI rs 2289252 and ABO rs 8176719 Have a Low Risk of VTE Recurrence | Jan Kvasnicka | ![]() |
![]() |
|||
PB-667 | Risk of Pulmonary Embolism after Surgical Resection of Meningioma | Andrea Artoni | ![]() |
![]() |
|||
PB-668 | Lower-leg Injury Leads to a Procoagulant State | Carolina E. Touw | ![]() |
![]() |
|||
PB-670 | The Effect of Alpha-2 Plasmin Inhibitor Activity and Antigen Levels and p.Arg6Trp Polymorphism on the Risk of Venous Thromboembolism | Éva Katona | ![]() |
![]() |
|||
PB-671 | Risk Stratification for Prevention of Venous Thromboembolism in Hospitalized Medical Patients: Can Thromboprophylaxis in Hospitalized Medical Patients Be Safely Restricted to Reduce Costs? | Alison Mary Bond | ![]() |
![]() |
|||
PB-672 | Predictors of Venous Thromboembolism in Patients Undergoing Neurosurgery for Glioma | Marco Capecchi | ![]() |
![]() |
|||
PB-673 | IVSS Safety Zone Protocol vs Padua Score in the Prevention of Thromboembolic Disease in Medical Patients: A Comparative Prospective Study | Juan Serrano | ![]() |
![]() |
|||
PB-680 | 25mmHg vs. 35 mmHg Graduated Elastic Compression Stockings to Treat Acute Symptoms of Deep-Vein Thrombosis: The CELEST Double-blind Trial | Jean-Philippe galanaud | ![]() |
![]() |
|||
PB-681 | Individualized Prediction Model for Risk of First DVT Using Clinical Assessment and D-dimer | Sameer Parpia | ![]() |
![]() |
|||
PB-682 | Long-term Risk of Post-thrombotic Syndrome after Symptomatic Distal Deep-vein Thrombosis: The CACTUS-PTS Study | Jean-Philippe Galanaud | ![]() |
![]() |
|||
PB-683 | Age-adjusted versus Clinical Probability-adjusted D-dimer to Exclude Pulmonary Embolism | Scott M Stevens | ![]() |
![]() |
|||
PB-684 | Vena Caval Filters in Patients Presenting with Major Bleeding during Anticoagulation for Venous Thromboembolism | Farès Moustafa | ![]() |
![]() |
|||
PB-685 | Whole Leg Ultrasound for the Diagnosis of Deep Vein Thrombosis Recurrence | Michelangelo Sartori | ![]() |
![]() |
|||
PB-688 | Clinical Predictors of Right Ventricular Dysfunction in Acute Pulmonary Thromboembolism | Jose Bonorino | ![]() |
![]() |
|||
PB-689 | Individualized Thromboprophylaxis in Patients with Lower-leg Cast Immobilization - A Validation and Subgroup Analysis in the POT-CAST Trial | Banne Nemeth | ![]() |
![]() |
|||
PB-690 | Prevalence of Pulmonary Embolism in Patients Presenting to the Emergency Department with Syncope in an Integrated Healthcare System | Scott S. Stevens | ![]() |
![]() |
|||
PB-693 | Assessment of D-dimer Value at First Venous Thromboembolism and Risk of Recurrence | Rosa Vidal | ![]() |
![]() |
|||
PB-695 | A Systematic Review to Determine Patient Preferences to Receive Thromboprophylaxis to Prevent Deep Vein Thrombosis and Pulmonary Embolism | Natasha Dembrey | ![]() |
![]() |
|||
PB-696 | Efficacy and Safety of Rivaroxaban and Apixaban in Relation to Low Molecular Heparin and Vitamin K Antagonists in Acute Venous Thromboembolism - A Single Center Prospective Study | Waldemar Wysokinski | ![]() |
![]() |
|||
PB-697 | Circulating Endothelial Cells as a New and Early Candidate Biomarker of Residual Pulmonary Vascular Obstruction after Pulmonary Embolism | Nicolas Gendron | ![]() |
![]() |
|||
PB-698 | Thrombophlebitis Post Varicose Vein Surgery: To Treat or Not to Treat? | Hui Yin Lim | ![]() |
![]() |
|||
PB-699 | Comparison of Risk Assessment Methods to Prevent Venous Thromboembolism (VTE) in Surgical Patients with Short Length of Hospital Stay | Maria Chiara Chindamo | ![]() |
![]() |
|||
PB-701 | Effectiveness and Safety of Outpatient Rivaroxaban versus Warfarin in Patients with Provoked Acute Venous Thromboembolism | Craig I Coleman | ![]() |
![]() |
|||
PB-702 | Rivaroxaban and Apixaban for Treatment of Acute Isolated Calf Deep Vein Thrombosis - A Single Center Prospective Study | Robert McBane | ![]() |
![]() |
|||
PB-704 | The Relationship between Neutrophil Lymphocyte Ratio and Deep Vein Thrombosis in Unilateral Limb Edema in Suspected Deep Vein Thrombosis Patients | Ikhwan Rinaldi | ![]() |
![]() |
|||
PB-705 | Application of an Explanatory Model for Emergency Physician Pulmonary Embolism Testing in a National Cohort | Sahar Zarabi | ![]() |
![]() |
|||
PB-706 | Deep Dive into DVTs: A 3 Year Retrospective Review of Patients with Deep Vein Thrombosis (DVT) on an Ambulatory Integrated Care Pathway (ICP) | V Graham | ![]() |
![]() |
|||
PB-707 | The Association of Characteristics of Central Venous Catheters with Venous Thrombotic Events in Pediatric Patients Undergoing Fontan Surgery | Ketan Kulkarni | ![]() |
![]() |
|||
PB-708 | Implementation of an Acute DVT Ambulatory Care Pathway in a Large Urban Centre: Current Challenges and Future Opportunities | Sarah Kelliher | ![]() |
![]() |
|||
PB-709 | Treatment Satisfaction with Rivaroxaban for the Management of Venous Thromboembolism (VTE) - Early Results from the ´Follow-up in Rivaroxaban Patients in Setting of Thromboembolism´ (FIRST) Registry | Victoria Speed | ![]() |
![]() |
|||
PB-711 | Evaluation of an Educational Video for Patients Taking Warfarin | Maria Auxiliadora Parreiras Martins | ![]() |
![]() |
|||
PB-712 | Subsegmental Pulmonary Embolism: An Innocent Bystander? | Myrthe Carlijn Gerritsen | ![]() |
![]() |
|||
PB-714 | Outpatient Management of Deep Vein Thrombosis using Direct Oral Anticoagulants is Safe and Cost-effective | Hui Yin Lim | ![]() |
![]() |
|||
PB-715 | Knowledge Derived from a Hospitalar Thromboprophylaxis Program | Maria Chiara Chindamo | ![]() |
![]() |
18-21 July 2018 Dublin
![]() |
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|